Press Releases
Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars...
Amgen and Daiichi Sankyo Company, Limited announced the execution of an exclusive agreement to commercialize nine biosimilars in Japan. The deal includes several biosimilars in...
Press Releases
AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for...
AbbVie a global biopharmaceutical company, announced that the U.S. FDA granted Rare Pediatric Disease Designation for ABT-414, an investigational antibody drug conjugate (ADC) targeting the...
Press Releases
Mylan NV Launches Generic Temodar Capsules
Mylan N.V. announced the U.S. launch of Temozolomide Capsules, 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg, which is a...
Press Releases
EC Grants Marketing Authorization for Gilead’s Epclusa for the...
Gilead Sciences, Inc announced that the European Commission has granted marketing authorization for Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg), the first pan-genotypic, single tablet regimen...
Press Releases
Sanofi and WRAIR sign research agreement to co-develop Zika...
Sanofi and its vaccines global business unit Sanofi Pasteur Research and Development Agreement with the Walter Reed Army Institute of Research (WRAIR) on the co-development...
Press Releases
FDA Approves Gilead’s Epclusa for the Treatment of All...
Gilead Sciences, Inc. announced that the U.S. FDA has approved Epclusa , the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with...
Press Releases
Novartis’ midostaurin achieves 60% response rate in advanced systemic...
Novartis announced that The New England Journal of Medicine published data for PKC412 demonstrating an overall response rate, defined as a major or partial response,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.